Amengual et al. demonstrated that targeting HDAC6 with ricolinostat in a panel of 16 lymphoma cell lines (DLBCL, MCL, T-cell lymphoma) inhibited HDAC6 activity and sequestration of misfolded proteins by disrupting transport to the aggresome through acetylation of α-tubulin. Here, HDAC6 is linked to mantle cell lymphoma.